Oncology Institute, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
M33 Growth I LP and TOI M, LLC have reduced their beneficial ownership in The Oncology Institute, Inc. through an in-kind distribution of shares to their respective partners.
NASDAQ
SCHEDULE 13D/A: M33 Growth, TOI M Divest $20.7M in Oncology Institute Shares
M33 Growth I LP and TOI M, LLC sold a combined 6.7 million shares of The Oncology Institute, Inc. common stock for $3.09 per share, with M33 LP entering a 180-day lock-up agreement.
NASDAQ
SCHEDULE 13D/A: Oncology Institute Investor Group Reduces Stake Below 5% Following Private Placement Dilution
Ravi Sarin and OncologyCare Partners, LLC have ceased to be beneficial owners of more than 5% of The Oncology Institute, Inc.'s common stock due to dilution from a recent private placement.
NASDAQ
M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC have increased their beneficial ownership in The Oncology Institute, Inc. to 19.99% through a recent private placement of common stock and warrants.